Apimeds Pharmaceuticals US, Inc. Market Cap ($4.54 Million)
Market Cap & Net Worth: Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. market cap. Apimeds Pharmaceuticals US, Inc. (NYSE MKT:APUS) has a market capitalization of $4.54 Million ($4.54 Million) as of October 31, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #28716 globally and #5906 in its home market, demonstrating a -4.75% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Apimeds Pharmaceuticals US, Inc.'s stock price $3.01 by its total outstanding shares 1509117 (1.51 Million).
Apimeds Pharmaceuticals US, Inc. Market Cap History (2025–2026)
Apimeds Pharmaceuticals US, Inc. market cap history from 2025 to 2026. Data shows growth from $2.47 Million to $4.54 Million (0.00% CAGR). Check APUS stock price for real-time trading data and today's change.
Apimeds Pharmaceuticals US, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Apimeds Pharmaceuticals US, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Apimeds Pharmaceuticals US, Inc. cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of APUS by Market Capitalization
Companies near Apimeds Pharmaceuticals US, Inc. in the global market cap rankings as of October 31, 2026. See net asset quality index of Apimeds Pharmaceuticals US, Inc. to understand what proportion of total assets are financed by equity.
Key companies related to Apimeds Pharmaceuticals US, Inc. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Apimeds Pharmaceuticals US, Inc. (2025–2026)
Market capitalization of Apimeds Pharmaceuticals US, Inc. from 2025 to today. Between 2025 and today, Apimeds Pharmaceuticals US, Inc.'s market cap moved from $2.47 Million to $ 4.54 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.54 Million | +83.54% |
| 2025 | $2.47 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Apimeds Pharmaceuticals US, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.54 Million USD |
| MoneyControl | $4.54 Million USD |
| MarketWatch | $4.54 Million USD |
| marketcap.company | $4.54 Million USD |
| Reuters | $4.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.